Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm Group to Support Ascepion in the Development of Debio 1144

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
Development of Debio 1144 for the treatment of Chinese cancer patients.

Suzhou Ascepion Pharmaceuticals, Inc. (Ascepion) and Debiopharm Group™ (Debiopharm) have announced that Debiopharm will support further development in China of Debio 1144, a small molecule in preclinical development for the treatment of a large spectrum of solid tumors.

Debiopharm and Ascepion had previously signed a license agreement for the development and commercialization of Debio 1144, an orally available multikinase inhibitor.

After having generated positive preclinical results with the product, Debiopharm has decided to support Ascepion for further development of Debio 1144 in China as it is well designed for the treatment of certain types of cancers that are highly represented in China.

“This is an opportunity for Ascepion to develop an anti-cancer agent tailored to the Chinese market,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

Mauvernay continued, “At Debiopharm we value sharing our competences with a Chinese company in view of developing a product with a potential to treat various cancers highly prevalent in emerging markets.”

“The disease spectrum of the Chinese population suggests the product will be well suited for its market. Thus it holds a great promise for certain cancer types in Chinese patients,” commented Dr. Shan Jiang, President and CEO of Ascepion Pharmaceuticals.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Debiopharm and EORTC Announce a Collaboration
Collaboration to investigate triptorelin for treatment of salivary gland cancers.
Thursday, January 14, 2016
EMA Grants Orphan Drug Designation to Debio 1143
Company grants EMA Designation to Debio 1143 for treatment of Ovarian Cancer.
Thursday, December 10, 2015
United and Debiopharm Announce the Launch of Pamorelin®
Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines.
Tuesday, December 08, 2015
Debiopharm’s Partner Yakult Announces Elplat® Approbation in Gastric Cancer
Approval for a supplemental new drug application for Elplat® in postoperative adjuvant chemotherapy in Japan.
Saturday, November 28, 2015
JCA and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award
The ‘JCA-Mauvernay Award 2015’ is awarded to Doctors Yutaka Kondo and Junko Takita.
Saturday, October 10, 2015
Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
Company presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347.
Tuesday, April 21, 2015
Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada
Trelstar® one-, three-, and six-month dosing options now available.
Wednesday, October 08, 2014
Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Curis and Debiopharm Report Preclinical Data for Debio 0932
Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.
Wednesday, April 09, 2014
Experimental Therapeutics Centre and Debiopharm Group™ to Collaborate
Collaboration for the development of an epigenetic innovative oncology target.
Tuesday, October 08, 2013
Diagnoplex S.A. Closes a Financing Round Led by Debiopharm Group™
Diagnoplex secures 1.3 million Swiss francs from financing round.
Friday, June 07, 2013
Chugai and Debiopharm Announce an Exclusive License Agreement for FF284
Chugai will grant Debiopharm an exclusive license to develop and commercialize FF284 in all countries.
Tuesday, January 08, 2013
First Patient Treated in Phase III Study with SC Administration of Debio 8206
Administration of Debio 8206 by SC route will prove very convenient in prostate cancer patients.
Thursday, December 27, 2012
Debiopharm and Ascepion Announce an Exclusive License Agreement
Agreement for the development and commercialization of the dual-targeting kinase Inhibitor, ASP-08126 (Debio 1144), for the treatment of oncology diseases.
Tuesday, June 19, 2012
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of Debio 0932
Company expects to initiate a combination Phase I/II study in NSCLC patients in the second quarter of 2012.
Tuesday, February 21, 2012
Scientific News
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Uncovering How Some Breast Cancers Resist Treatment
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Activating Cancer-Killing Immune Cells
A UCL research team have discovered that cutting off a sleep-switch on immune cells inside a tumour wakes up the cells and enables the immune system to hunt down and destroy cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!